A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib ... trial would be discussed soon. The primary endpoint of the Phase III ADAURA trial is disease-free survival ...

This tool is a type of molecular residual disease (MRD) detector, which is used after patients have completed their primary ... from the ADAURA clinical trial of the targeted therapy osimertinib ...

Osimertinib (Tagrisso ... Ramalingam presented updated progression-free survival (PFS) data — the primary study endpoint — in June 2024 at the annual American Society of Clinical Oncology ...